Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of chidamide
plus camrelizumab as second-line therapy for advanced esophageal squamous cell carcinoma
treated with PD-1 blockade
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University